SEC Company Response from ADC Therapeutics SA (ADCT) (CIK 0001771910) (ADCT) — Sep 30, 2019
ADC Therapeutics SA (ADCT) (CIK 0001771910)
Date: Sept. 30, 2019 · CIK: 0001771910 · Accession: 0001140361-19-017562
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233659
Letter
Re:
September 30, 2019
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Ms. Tonya K. Aldave
ADC Therapeutics SA
Registration Statement on Form F-1 (File No. 333-233659)
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended, we wish to advise that as of the date hereof, approximately 2,397 copies of the Preliminary Prospectus dated September 23, 2019 were distributed to prospective underwriters, institutional investors and prospective dealers in connection with the above-captioned Registration Statement.
We wish to advise you that the participating underwriters have informed us that they have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
We hereby join in the request of the registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 3:30 p.m. Eastern Time, on Wednesday, October 2, 2019 or as soon thereafter as practicable.
[Signature page follows]
Very truly yours,
Morgan Stanley & Co. LLC
Show Raw Text
CORRESP
1
filename1.htm
September 30, 2019
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Ms. Tonya K. Aldave
Re:
ADC Therapeutics SA
Registration Statement on Form F-1 (File No. 333-233659)
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended, we wish to advise that as of the date hereof, approximately 2,397 copies of the Preliminary Prospectus
dated September 23, 2019 were distributed to prospective underwriters, institutional investors and prospective dealers in connection with the above-captioned Registration Statement.
We wish to advise you that the participating underwriters have informed us that they have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
We hereby join in the request of the registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 3:30 p.m. Eastern Time, on Wednesday, October 2, 2019 or as soon
thereafter as practicable.
[Signature page follows]
Very truly yours,
Morgan Stanley & Co. LLC
BofA Securities, Inc.
Cowen and Company, LLC
As representatives of the Underwriters
By:
Morgan Stanley & Co. LLC
By:
/s/ Chris Rigoli
Name:
Chris Rigoli
Title:
Vice President
By:
BofA Securities, Inc.
By:
/s/ Michael Liloia
Name:
Michael Liloia
Title:
Director
By:
Cowen and Company, LLC
By:
/s/ Bill Follis
Name:
Bill Follis
Title:
Managing Director
[Signature Page to ADC Therapeutics SA Acceleration Request]